Salix still peer perform by Thomas Weisel

Salix Pharmaceuticals was maintained by Thomas Weisel Partners analyst Donald B. Ellis at a peer perform rating after the company announced that it licensed NRL944, a liquid PEG bowel cleansing product from Norgine NV. The product is under review by the FDA and is patent-protected through 2013, with additional protections that could extend until 2023. This is the fifth business development transaction for the company in two years, which shows that the company is building a base to drive long-term growth, Thomas Weisel said. Shares of the Morrisville, N.C., pharmaceutical company were down 32 cents, or 1.73%, at $18.14 on volume of 420,782 shares versus the three-month running average of 465,254 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.